Sarah Hall
Psychiatric/Mental Health · Meridian, IDNPI 1346768330
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 29.9% of the total.
Across 185 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- AbbVie$452
- Alkermes, Inc.$380
- Teva Pharmaceuticals USA, Inc.$354
- Otsuka America Pharmaceutical, Inc.$305
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$261
- plus $735 from 10 others
What the payments were for
- Food & beverage$3,46798%
- Education$842%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 67 | $1,063 |
| AbbVie | 33 | $452 |
| Alkermes, Inc. | 12 | $380 |
| Teva Pharmaceuticals USA, Inc. | 13 | $354 |
| Otsuka America Pharmaceutical, Inc. | 16 | $305 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $261 |
| Johnson & Johnson | 6 | $215 |
| Vanda Pharmaceuticals Inc. | 6 | $107 |
| Janssen Scientific Affairs, LLC | 4 | $107 |
| Eisai Inc. | 1 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $90 |
| Lundbeck LLC | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Corium, LLC | 2 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$891
- INGREZZA$131
- INVEGA SUSTENNA$118
- INVEGA TRINZA$118
- UZEDY$113
- Dayvigo$104
How this compares
$3,551 in reported general payments places this provider in the 85th percentile of 221 psychiatric/mental health providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 53 | $435,833 |
| Invega SustennaPaliperidone Palmitate | 25 | $83,957 |
| VraylarCariprazine Hcl | 61 | $79,785 |
| LybalviOlanzapine/Samidorphan Malate | 34 | $50,185 |
| CaplytaLumateperone Tosylate | 14 | $23,471 |
| Paliperidone ErPaliperidone | 27 | $17,305 |
| Lurasidone Hcl | 67 | $14,440 |
| TrintellixVortioxetine Hydrobromide | 32 | $13,975 |
| Topiramate ErTopiramate | 12 | $9,469 |
| Aripiprazole | 56 | $8,938 |
| Lisdexamfetamine Dimesylate | 32 | $7,180 |
| Olanzapine | 78 | $6,650 |
| VyvanseLisdexamfetamine Dimesylate | 17 | $6,416 |
| QuviviqDaridorexant Hcl | 12 | $5,445 |
| Ramelteon | 26 | $5,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,063 | $435,83353 claims |
| Johnson & JohnsonInvega Sustenna | $215 | $83,95725 claims |
| AbbVieVraylar | $452 | $79,78561 claims |
| Alkermes, Inc.Lybalvi | $380 | $50,18534 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $261 | $23,47114 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $90 | $20,39149 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $15 | $5,44512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 221 psychiatric/mental health providers in Idaho.
Other psychiatric/mental health in Meridian
- Deborah RushMeridian$13K
- Jynnah SnowMeridian$4K
- Gretchen GayleMeridian$4K
- Jarrod CrumpMeridian$3K
- Stephanie LeeMeridian$3K
- Kyle RonnauMeridian$3K
- Ann CoreyMeridian$3K
- Kyanne WrightMeridian$2K
- Nicole JustesenMeridian$2K
- Salome GichuruMeridian$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.